An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up

K. A. Bojang; S. K. Obaro; U. D'Alessandro; S. Bennett; P. Langerock; G. A.T. Targett; B. M. Greenwood

doi:10.1016/S0264-410X(97)00159-X

An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up

K. A. Bojang, S. K. Obaro, U. D'Alessandro, S. Bennett, P. Langerock, G. A.T. Targett, B. M. Greenwood

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI - 20%, 30%] and 2% [95% CI - 26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

Original language	English (US)
Pages (from-to)	62-67
Number of pages	6
Journal	Vaccine
Volume	16
Issue number	1
DOIs	https://doi.org/10.1016/S0264-410X(97)00159-X
State	Published - Jan 1 1998
Externally published	Yes

Keywords

Malaria
Malaria vaccine
Plasmodium falciparum
Spf66

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(97)00159-X

Cite this

@article{77c753e5a8f340c4baeecb1f8e9a579f,

title = "An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up",

abstract = "In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI - 20%, 30%] and 2% [95% CI - 26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.",

keywords = "Malaria, Malaria vaccine, Plasmodium falciparum, Spf66",

author = "Bojang, {K. A.} and Obaro, {S. K.} and U. D'Alessandro and S. Bennett and P. Langerock and Targett, {G. A.T.} and Greenwood, {B. M.}",

note = "Funding Information: We thank Professor M.E. Patarroyo and his colleagues at the Instituto de Imunologia, Bogota, Colombia for provision of SPf66 and Mr G. Fegan for help in establishing the data-management system. We thank also the children and their parents; field staff Kebba Keita, Alhagie Darboe, Pa Amadou Susso, Waza Njie, Famalang Camara, Dembo Fatty, Pa Camara, Kebba Naban and Seedy Singateh; Nurse Karamo Bayo, Abu Khan Jallow and Famara Wally; Helene Obaro, Momodou Hydara and Fatou Jagne for help with data entry; Dr Margaret Pinder, Momodou Jallow, and Simon Correa for help with microscopy. This study was supported by the UK Medical Research Council.",

year = "1998",

month = jan,

day = "1",

doi = "10.1016/S0264-410X(97)00159-X",

language = "English (US)",

volume = "16",

pages = "62--67",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up

AU - Bojang, K. A.

AU - Obaro, S. K.

AU - D'Alessandro, U.

AU - Bennett, S.

AU - Langerock, P.

AU - Targett, G. A.T.

AU - Greenwood, B. M.

N1 - Funding Information: We thank Professor M.E. Patarroyo and his colleagues at the Instituto de Imunologia, Bogota, Colombia for provision of SPf66 and Mr G. Fegan for help in establishing the data-management system. We thank also the children and their parents; field staff Kebba Keita, Alhagie Darboe, Pa Amadou Susso, Waza Njie, Famalang Camara, Dembo Fatty, Pa Camara, Kebba Naban and Seedy Singateh; Nurse Karamo Bayo, Abu Khan Jallow and Famara Wally; Helene Obaro, Momodou Hydara and Fatou Jagne for help with data entry; Dr Margaret Pinder, Momodou Jallow, and Simon Correa for help with microscopy. This study was supported by the UK Medical Research Council.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI - 20%, 30%] and 2% [95% CI - 26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

AB - In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI - 20%, 30%] and 2% [95% CI - 26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

KW - Malaria

KW - Malaria vaccine

KW - Plasmodium falciparum

KW - Spf66

UR - http://www.scopus.com/inward/record.url?scp=0031986509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031986509&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(97)00159-X

DO - 10.1016/S0264-410X(97)00159-X

M3 - Article

C2 - 9607010

AN - SCOPUS:0031986509

SN - 0264-410X

VL - 16

SP - 62

EP - 67

JO - Vaccine

JF - Vaccine

IS - 1

ER -

An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this